|Chemical and physical data|
|Molar mass||666.77 g/mol|
|3D model (JSmol)|
|‹See TfM› (what is this?)|
In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome (ACS). An additional trial of 13,000 patients (SOLID-TIMI 52) finished in May 2014. The study failed to reduce the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization compared with placebo in acute coronary syndrome patients treated with standard medical care.
- Thompson PL et al. Targeting the unstable plaque in acute coronary syndromes. Clin Ther. 2013 Aug;35(8):1099-107. PMID 23973042
- Reuters. 12 April 2007 Spotlight on Glaxo Heart Drug as Others Fail
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|